Trial
NCT05124210
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
Vir Biotechnology, Inc.
Condition
COVID-19
Intervention
Sotrovimab
Why stopped
Decrease in in-vitro neutralization of study drug against circulating SARS-CoV-2 variants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-03